Quantcast
Last updated on April 16, 2014 at 13:10 EDT

Latest Crohn's disease Stories

2013-04-04 08:29:34

Three new studies review use, comparative effectiveness and cost SAN DIEGO, April 4, 2013 /PRNewswire/ -- In recent years, biologic anti-inflammatory (BAI) specialty medications used to treat autoimmune inflammatory conditions such as rheumatoid arthritis (RA), psoriasis and Crohn's disease, have seen double-digit percentage price increases. The potential exists to treat many more patients than are currently receiving a BAI medication, according to new studies presented today by...

2013-03-19 08:27:35

GLEN ALLEN, Va., March 19, 2013 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI), through its wholly owned subsidiary, Rock Creek Pharmaceuticals, Inc., announced today that it has received positive preliminary results from a study investigating the effects of anatabine in an animal model of idiopathic inflammatory bowel disease, Crohn's disease and ulcerative colitis. This study, performed by researchers in the Department of Medicine at the University of Virginia, assessed the effects...

2013-03-07 12:26:58

OSAKA, Japan, March 7, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), the two most common types of inflammatory bowel disease (IBD). If...

2013-03-05 12:28:06

EXTON, Pa., March 5, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, although there have been no significant changes with regard to biologic treatment and Crohn's disease (CD) patients with active disease since 2012, surveyed gastroenterologist data indicate a significant 43 percent increase in biologic treatment among CD patients in remission since 2012, suggesting that biologic agents...

2013-01-31 00:20:19

NEW YORK, Jan. 30, 2013 /PRNewswire-iReach/ -- Having struggled with Crohn's Disease since the early 90's, Warren Sulmasy joined the Crohn's and Colitis Foundation of America (CCFA) in January 2013 to help find a cure for those who struggle with the chronic diseases. In the early 90's, Sulmasy's health began to deteriorate over a period of several months. He lost, 50 pounds and was constantly fatigued. He endured rounds of tests and medication from 12 different doctors until he was finally...

2013-01-08 12:25:57

NEW YORK and BETHESDA, Md., Jan. 8, 2013 /PRNewswire/ -- TNI BioTech, Inc. (PINKSHEETS: TNIB) announced today that it has signed an agreement for the acquisition of patent rights and orphan drug designation by the FDA to a novel late-stage drug, trademarked "LDN," for the treatment of Pediatric Crohn's Disease. TNI BioTech has signed a licensing agreement to acquire the exclusive patent rights for the intellectual property of Dr. Jill Smith and LDN Research LLC, whose...

2012-12-27 08:24:28

PRINCETON, N.J., Dec. 27, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, today announced that it has regained the North American and European commercial rights to oral BDP (beclomethasone 17.21-dipropionate) through an amendment of its Collaboration and Supply Agreement with Sigma-Tau Pharmaceuticals, Inc. Soligenix is now free to commercialize or enter into commercialization agreements for its oral BDP suite of...

2012-12-22 05:00:33

A guide published in December 2012 by Clear Passage Physical Therapy® provides an extensive overview of diet guidelines for people with digestive problems, including those with recurring, life-threatening bowel obstruction. Gainesville, FL (PRWEB) December 21, 2012 For people with digestive disorders or bowel obstruction, eating the wrong foods can create major problems, or even be life-threatening. To help clarify diet choices, Clear Passage Physical Therapy® has developed a...

2012-12-21 16:22:38

BEDMINSTER, N.J., Dec. 21, 2012 /PRNewswire/ -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved Gattex(®) (Teduglutide [rDNA origin]) for Injection, for subcutaneous use for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. Gattex will...

2012-12-18 08:27:29

PRINCETON, N.J., Dec. 18, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today the acquisition of a novel drug technology, known as SGX94, representing a unique approach to modulation of the innate immune system. SGX94 is an innate defense regulator (IDR) that regulates the innate immune system to reduce inflammation, eliminate infection and enhance tissue healing by binding to the pivotal regulatory...